Background
==========

Tetralogy of Fallot (TOF) is the most frequently form of cyanotic heart defect or cyanotic congenital heart disease, and is the major cause of blue baby syndrome \[[@b1-medscimonit-21-3474]\]. TOF is characterized by a misalignment of the conal septum, resulting in a rightward deviation of the aorta, which may lead to a large ventricular septal defect and varying degrees of right ventricular outflow tract narrowing \[[@b2-medscimonit-21-3474]\]. The incidence of TOF is estimated at 5\~7 per 10 000 live births and TOF accounts for 5\~7% of all congenital heart lesions \[[@b3-medscimonit-21-3474]\]. Importantly, patients with TOF generally receive surgical repair in the first year of life, with additional requirement of surgical intervention as the child grows \[[@b4-medscimonit-21-3474]\]. Since the first description of procedures in the 1950s, the diagnosis, surgical treatment, and postoperative care of TOF have significantly improved; hence, patients born with TOF can now expect to survive to adulthood \[[@b5-medscimonit-21-3474]--[@b7-medscimonit-21-3474]\]. However, despite excellent short- and medium-term survival rates, the 30-year actuarial survival for patients repaired before their 5th birthday is 90% of the expected survival rate and the annualized risk of death triples in the third postoperative decade \[[@b8-medscimonit-21-3474]\]. The exact pathophysiology of TOF is not well understood, but both genetic and environmental factors play major roles in TOF \[[@b9-medscimonit-21-3474],[@b10-medscimonit-21-3474]\]. Viral infections, urticarial vasculitis, radiation exposure, lifestyle, and other environmental factors are associated with a high risk of TOF \[[@b11-medscimonit-21-3474]\]. Recent evidence suggests that *VEGF* gene is a key player in the etiology of TOF \[[@b12-medscimonit-21-3474],[@b13-medscimonit-21-3474]\].

Vascular endothelial growth factor (VEGF) belongs to a sub-family of the platelet-derived growth factors and is a prominent endothelial cell-specific mitogen and inducer of vascular permeability, and is an important signaling molecule involved in vasculogenesis and angiogenesis \[[@b14-medscimonit-21-3474]\]. In the angiogenic network, the VEGF are by far the best characterized and has been implicated in the pathogenesis of coronary artery disease and in its complication, acute myocardial infarction \[[@b15-medscimonit-21-3474]\]. As a multifunctional cytokine, VEGF exerts a variety of essential biological effects on vascular endothelium \[[@b16-medscimonit-21-3474]\]. VEGF induces angiogenesis in various physiological and pathological conditions, such as normal embryogenesis, compensatory angiogenesis, wound-healing, and in tumor growth and metastasis \[[@b14-medscimonit-21-3474],[@b17-medscimonit-21-3474]\]. Hypoxia up-regulates VEGF gene expression, which has tremendous physiological implications for a wide variety of pathological conditions in humans \[[@b18-medscimonit-21-3474]\]. Adequate VEGF serum levels are essential for heart development, and alterations in VEGF levels may contribute to cardiovascular developmental defects \[[@b19-medscimonit-21-3474],[@b20-medscimonit-21-3474]\]. In this context, up-regulated VEGF levels, during the development of right ventricular outflow tract, result in abnormal development of both cushion and myocardial structures \[[@b21-medscimonit-21-3474],[@b22-medscimonit-21-3474]\]. Therefore, genetic polymorphisms in *VEGF* are an important way to understand the role of the *VEGF* gene in heart development. The human *VEGF* gene is located on chromosome 6p21.3 and consists of 8 exons and 7 introns \[[@b23-medscimonit-21-3474]\]. Earlier studies have demonstrated that there are 5 common genetic polymorphisms involved in various human diseases: −2578C\>A (rs699947), −460T/C (rs833061), −634G\>C (rs2010963), +405C/G (rs2010963), and +936C\>T (rs3025039) \[[@b24-medscimonit-21-3474]--[@b26-medscimonit-21-3474]\]. Takuya Awata et al. demonstrated the correlation of the VEGF 634CC genotype with higher VEGF production is consistent with the genetic association of the 634C allele \[[@b27-medscimonit-21-3474]\]. *VEGF* gene polymorphism of −2549 (rs3034659) have been reported to be associated with variations in VEGF plasma concentrations and with a susceptibility to disorders, such as diabetic retinopathy, diabetic nephropathy, and cardiovascular diseases \[[@b28-medscimonit-21-3474]\]. In general, genetic variations in *VEGF* may influence VEGF expression and activity, and variously confer susceptibility to congenital heart diseases \[[@b20-medscimonit-21-3474],[@b29-medscimonit-21-3474]\]. We hypothesized that *VEGF* polymorphisms may be associated with the risk of TOF. We carried out this study to gather evidence in relation to our hypothesis and thus investigated the relationship between *VEGF* polymorphisms and the risk of TOF in Chinese Han children.

Material and Methods
====================

Study subjects and ethics statement
-----------------------------------

A total of 160 Chinese Han children with TOF were recruited for this study as the case group (TOF group) at the Department of Cardiovascular, Affiliated Hospital of Jining Medical University between January 2010 and June 2013. The TOF patients exhibited typical clinical symptoms and were all diagnosed with color Doppler echocardiography and surgery. Patients with abnormalities other than cardiovascular abnormalities were excluded. There were no abnormalities found by karyotype analysis of the included TOF patients. Among the 160 TOF children, 103 patients were males and 57 patients were females, with an average age of 4.27±1.93 years old (age range, 1 to 8 years). Another group of 240 healthy Han children, who received health examination at the medical examination center of our hospital during the same period, were selected as the control group. The Han children who suffered from congenital heart disease or other cardiac structural abnormalities, as confirmed by clinical manifestations and echocardiography, were excluded from this study. The control group included 148 males and 92 females, with an average age of 5.68±2.17 years old (age range, 2 to 10 years). There were no significant differences in age or sex between the TOF group and control group (*P*\>0.05). This study was approved by the Ethics Committee of the Affiliated Hospital of Jining Medical University. All parents of all included Han children signed the informed consent prior to the study and the study conformed to the Declaration of Helsinki \[[@b30-medscimonit-21-3474]\].

DNA extraction
--------------

A total of 2 ml peripheral venous blood from all included subjects was drawn in the morning, following an overnight fast, and was placed in ethylenediamine tetraacetic acid (EDTA)-containing tubes for anticoagulation, and stored at −20°C until further use. The 2-ml blood samples were centrifuged at 2500r/m for 5 min to serum and cells, and the collected serum was evenly split into 3-ml cryotubes and stored at −20°C for later use. Genomic DNA was extracted from leukocytes using the conventional saturated phenol-chloroform extraction method. The concentration and purity of DNA was measured and the isolated genomic DNA was stored at −20°C for further use.

SNP selection and primer design
-------------------------------

We investigated 3 relevant SNP candidates in the *VEGF* gene. All SNP sequences selected for genotyping were initially identified using the HapMap database (*<http://www.hapmap.org/>*). The linkage disequilibrium of *VEGF* polymorphisms is illustrated in [Figure 1](#f1-medscimonit-21-3474){ref-type="fig"}. The SNP genotypes of the *VEGF* functional polymorphic *loci*, −2578C\>A, −634C\>G, and 936C\>T, were detected by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). The full-length *VEGF* gene sequence was retrieved from GenBank (Accession Number AF 437895) and, based on the gene sequence, the PCR amplification primers for each polymorphic *loci* were designed using Primer 5.0 software (Takara, Dalian), as shown in [Table 1](#t1-medscimonit-21-3474){ref-type="table"}.

Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP)
-----------------------------------------------------------------------------

The gradient PCR was performed using a Thermocycler MJPTC-200 PCR System. The PCR amplification of the genetic polymorphisms of *VEGF* was performed after determining the optimal annealing temperature. The PCR reaction system in a 15-μl volume contained the following components: 50 ng genomic DNA, 12.5 pmol of each primer, 0.1 mml of each nucleotide, l0×PCR buffer (50 mml KCl, 10 mml TrisHCl, 0.1% Triton X-100, 1.5 mml MgCl2, and 1.0 U Taq polymerase). Reaction conditions of PCR were as follows: initial denaturation at 95°C for 5 min, denaturation at 95°C for 30 s, annealing at annealing temperature, which were 53°C −2578\>A), 67°C (−634C\>G), and 53°C (936C\>T), respectively, for 40 s, and extension at 72°C for 45 s. After 34 cycles of amplification, final extension was at 72°C for 10 min. The PCR amplification product were first purified and 5 μl of the purified PCR amplification products were digested with 5 U of restriction enzymes Bg1II, BsmFI, and NlaIII (Shanghai Sangon Biotech, Shanghai, China) to distinguish between the genetic polymorphisms of *VEGF*. Restriction digestions were performed under standard digestion conditions, with an overnight incubation at 37°C. The results were analyzed by 3.0% agarose gel electrophoresis to detect PCR fragment pattern, and individual genotypes were determined from the size of the bands. The restriction enzymes for each locus are shown in [Table 1](#t1-medscimonit-21-3474){ref-type="table"}.

Genotyping
----------

Restriction fragment length polymorphism (RFLP) was employed to detect the genetic polymorphisms of −2578C\>A, −634C\>G, and 936C\>T in *VEGF* gene. The restriction enzyme Bg1II distinguished the A and C alleles and CC, CA, and AA genotypes were observed in the −2578C\>A polymorphism of *VEGF* gene. The mutant AA genotype showed 2 fragments of 194 bp and 102 bp, and the CA genotype showed 3 fragments of 296 bp, 194 bp, and 102 bp, while wild genotype (CC) showed only 1 band of 296 bp. With restriction enzyme BsmFI, 2 alleles (C and G) and 3 genotypes) CC, CG, and GG) were observed in the −634C\>G polymorphism of *VEGF* gene. The mutant GG genotype showed 166 bp and 108 bp bands, and the CG genotype showed 274 bp, 166 bp and 108 bp bands, while the wild CC genotype showed only 1 band of 274 bp. With restriction enzyme NlaIII, 2 alleles (C and T) and 3 genotypes (CC, CT and TT) were observed in the 936C\>T polymorphism of *VEGF* gene. The mutant TT genotype showed 2 fragments of 211 bp and 55 bp, and CT genotype showed 3 fragments of 266 bp, 211 bp, and 55 bp, while the wild CC genotype showed only 1 band of 266 bp. The results were further confirmed by sequencing and by alignment of the sequencing results with GenBank sequences using CLUSTAL method.

Statistical analysis
--------------------

All data were analyzed with SPSS17.0 software (SPSS, Chicago, IL, USA). Measurement data are expressed as mean ± standard deviation (Mean ±SD) and *t* test were applied to compare the general data of TOF group and control group. We adopted χ^2^ test for the differences of genotypes and allele frequencies. The Bonferroni correction was conducted and the statistical differences were presented if *P*~c~\<0.05. We also used χ^2^ test to confirm if the allele frequency of *VEGF* polymorphisms were in Hardy-Weinberg equilibrium (HWE). Linkage disequilibrium was evaluated by D and r^2^ values (r^2^ \>0.33 showed disequilibrium). A non-conditional logistic regression was used to calculate the odds ratios (OR) and 95% confidence interval (CI) represented the relative risk. All statistical tests were 2-sided and a value of *P*\<0.05 indicated statistical significance.

Results
=======

Baseline characteristics
------------------------

The baseline characteristics of TOF patients and normal controls are illustrated in [Table 2](#t2-medscimonit-21-3474){ref-type="table"}. No statistically significant differences in body mass index (BMI) or sex distribution were observed between the TOF group and the healthy control group (both *P*\>0.05). Importantly, there was a significant difference in age and in the family history of TOF between the 2 groups (both *P*\<0.05).

Distribution of genotypes and allele frequencies of *VEGF* genetic polymorphisms
--------------------------------------------------------------------------------

The electrophoresis patterns for the genotypes of *VEGF* genetic polymorphisms are as illustrated in [Figures 2](#f2-medscimonit-21-3474){ref-type="fig"}[](#f3-medscimonit-21-3474){ref-type="fig"}--[4](#f4-medscimonit-21-3474){ref-type="fig"}. The PCR-RFLP results of *VEGF* rs699947 (−2578C\>A) polymorphism showed that AA genotype showed 2 fragments of 202 bp and 122 bp, and the CA genotype showed 3 fragments of 324 bp, 202 bp, and 122 bp, while CC genotype remained undigested. The *VEGF* rs2010963 (−634C\>G) polymorphism showed 3 patterns: CC genotype with a single band of 180 bp, CG genotype with 180 bp, 120 bp, and 60 bp fragments, and GG genotype with 60 bp and 120 bp fragments. Further, the CC genotype of *VEGF* rs3025039 (936C\>T) remained undigested, while the TT genotype showed 2 fragments of 86 bp and 112 bp fragments and CT genotype showed 3 fragments of 198 bp, 86 bp, and 112 bp.

The distribution of genotypes and allele frequencies of the 3 *VEGF* gene polymorphisms, −2578C\>A, −634C\>G, and 936C\>T, are shown in [Table 3](#t3-medscimonit-21-3474){ref-type="table"}. The genotypes and allele frequencies of *VEGF* −2578C\>A, −634C\>G, and 936C\>T polymorphisms were in accordance with HWE, suggesting that each gene frequency had reached equilibrium and the selected sample represented the population (*P\>*0.05). The frequency of mutant AA genotype in *VEGF* −2578C\>A polymorphism in TOF group was significantly higher than the control group (48.8% *vs.* 32.9%, *P=*0.042), and the statistical significance was still present after Bonferroni correction (*P*~c~*=*0.372). The A allele frequency in −2578C\>A in the TOF group was markedly higher than that observed in the control group (71.2% *vs.* 61.7%, *P*=0.005), and the statistical significance was still present after Bonferroni correction (*P*~c~*=*0.045). The AA+CA genotype frequency of the TOF group was higher than the control group (93.8% *vs.* 90.4%), with no statistical difference (*P*=0.235). Additionally, the GG genotype frequency of *VEGF* −634C\>G in TOF group was significantly higher than the control group (53.8% *vs.* 36.7%, *P=*0.031), and the statistical significance was still present after Bonferroni correction (*P*~c~*=*0.279). The G allele frequency in −634C\>G in the TOF group was higher than in the control group (72.8% *vs.* 62.3%, *P*=0.002); the statistical significance was still present after Bonferroni correction (*P*~c~*=*0.018). The GG+CG frequency on −634C\>G in the TOF group was higher than in the control group (91.9% *vs.* 81.9%), but with no statistical difference (*P*=0.206). Conversely, the frequencies of TT genotype and T allele in *VEGF* 936C\>T in TOF group were both significantly lower than in the control group (TT genotype: 41.9% *vs.* 54.6%, *P=*0.030, *P*~c~=0.270; T allele: 48.1% *vs.* 58.7%, *P=*0.003, *P*~c~*=*0.027). However, there was no statistically significant difference in TT+CT genotypes frequencies between the 2 groups (54.4% *vs.* 62.9%, *P*=0.088).

Linkage analysis of SNP in VEGF gene
------------------------------------

Linkage disequilibrium was evaluated by D and r^2^ values. It is showed linkage disequilibrium when r^2^ \>0.33 ([Table 4](#t4-medscimonit-21-3474){ref-type="table"}). The rs699947 and rs2010963 locus presented linkage disequilibrium (r^2^=0.694), while the rs2010963and rs3025039 locus did not (r^2^=0.198).

Correlation analysis of *VEGF* polymorphisms with the risk of TOF
-----------------------------------------------------------------

Multiple logistic regression analysis was carried out to calculate the adjusted odds ratio. The TOF was the dependent variable, and the AA, CC, and TT genotype of *VEGF* −2578C\>A, −634G\>C, and 936C\>T were the independent variables. The multivariate logistic regression analysis results showed that the mutable gene of −2578C\>A and −634C\>G polymorphisms are independently related to the TOF risk (OR=1.951, 95%CI=1.280\~2.974, *P*=0.002; OR=2.144, 95%CI=1.411\~3.258, *P*\<0.001), and the TT genotypes of 936C\>T are also associated with TOF risk (OR=0.590, 95%CI=0.389--0.894, *P*=0.013) ([Table 5](#t5-medscimonit-21-3474){ref-type="table"}).

Discussion
==========

In this study, we examined the correlations of *VEGF* −2578C\>A (rs699947), −634G\>C (rs2010963), and +936C\>T (rs3025039) polymorphisms with TOF risk. The main results of our study confirmed that *VEGF* genetic polymorphisms −2578C\>A and −634C\>G may be associated with an increased TOF risk, while 936C\>T polymorphism may be associated with decreased TOF risk. The pathogenesis of TOF is multifactorial and involves various genetic and environmental factors. However, the exact cellular mechanisms leading to TOF are incompletely understood. The heart is the first organ to form and various signaling pathways, including VEGF, Notch, Wnt/β-catenin, and BMP/TGF-β, may be involved in heart development \[[@b31-medscimonit-21-3474]--[@b34-medscimonit-21-3474]\]. VEGF is an important player in endocardial and epicardial epithelial-mesenchymal transformation (EMT), which results in the establishment of most non-cardiomyocyte lineages of the mature heart during heart valve development \[[@b35-medscimonit-21-3474],[@b36-medscimonit-21-3474]\]. VEGF can also play a key role in endocardial cushion development, possibly by regulating cell proliferation, vasculogenesis, vascular permeability, and angiogenesis in embryonic development \[[@b36-medscimonit-21-3474],[@b37-medscimonit-21-3474]\]. Yang et al. found that VEGF expression was visualized as nuclear and cytoplasmic localized granular brown-yellow precipitate and their findings indicated that BMSC transplantation in dilated cardiomyopathy could promote the myocardial expression of VEGF \[[@b38-medscimonit-21-3474]\]. On the other hand, VEGF is also linked to the formation of collateral vessels in ischemic heart disease and cyanotic congenital heart disease \[[@b39-medscimonit-21-3474]\]. Several studies have also demonstrated that the expression of VEGF is regulated by hypoxia and alterations in VEGF expression level may be involved in the development of congenital heart disease, including TOF \[[@b40-medscimonit-21-3474],[@b41-medscimonit-21-3474]\]. Several variant genotypes and haplotypes of *VEGF* gene alter the basal level of *VEGF* expression. These alterations in the *VEGF* gene are also functionally reflected in the altered expression levels of VEGF protein in the serum, and may tightly regulate cardiac morphogenesis, as evidenced by various genetic mouse models \[[@b42-medscimonit-21-3474]--[@b44-medscimonit-21-3474]\].

The gene coding for VEGF is affected by common, functionally important genetic polymorphisms associated with cardiovascular disease and are early predictors of congenital heart disease. Among the most important polymorphisms are: −2578C\>A (rs699947), located in the promoter region; −634G\>C (rs2010963), located in exon 1; and +936C\>T (rs3025039), located in exon 8, in the 5′ untranslated region \[[@b45-medscimonit-21-3474]\]. In the current study, we found that the frequency of AA genotype in −2578C\>A in the TOF group was significantly higher than in the control group, and the TOF risk of patients with A allele carrier was 1.54-fold higher than that of C allele carrier, suggesting that the AA genotype and A allele in −2578C\>A polymorphism may be a potential risk factor for TOF development. Further, the frequency of GG genotype in −634C\>G in the TOF group was also significantly higher than the control group, and the risk of TOF of the patients with G allele was 1.62-fold higher than in patients with C allele, implying that the GG genotype and G allele in −634C\>G in polymorphism may be correlated with the increased risk of TOF. However, T allele in 936C\>T polymorphism decreased TOF risk, indicating that the T allele may be a protective factor for TOF. All of the above results had statistical significance after Bonferroni correction. Douvaras et al. showed that the −634C\>G polymorphism of *VEGF* gene and its co-inheritance with genotypes of other *VEGF* genetic polymorphisms might be potential risk factors for the development of heart failure after acute myocardial infarction \[[@b46-medscimonit-21-3474]\]. Further, Lambrechts et al. also showed that the common polymorphisms of −2578C\>A, −1154A, and −634C\>G in *VEGF* gene may be linked with the elevated risk of TOF \[[@b12-medscimonit-21-3474]\]. The polymorphism at position −634 of *VEGF* gene has been proved to be correlated with the pathological processes of ventricular septal defect in a Chinese population \[[@b47-medscimonit-21-3474]\]. Additionally, consistent with our study results, the polymorphism at position 936 C/T of *VEGF* gene has previously been shown to be related to lower VEGF plasma levels in healthy young individuals, which may be associated with reduced risk of human diseases \[[@b48-medscimonit-21-3474],[@b49-medscimonit-21-3474]\].

There are some limitations in the present study. First of all, the sample sizes of our study were relatively small, which may reduce the strength of our conclusions. Secondly, the statistical power was not conducted in this study, which also decreased the power of our study.

Conclusions
===========

Our results provide strong evidence that the polymorphisms of *VEGF* −2578C\>A (rs699947) and −634G\>C (rs2010963) are correlated to an increased risk of TOF, while the +936C\>T (rs3025039) polymorphism may be correlated with a decreased risk of TOF, suggesting these polymorphisms can serve as biomarkers to evaluate the susceptibility to TOF. Nevertheless, due to the small sample size of this study, further studies with larger sample sizes and more integral data are necessary for the development of statistical analysis with general applicability.
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![Linkage disequilibrium (LD) analysis of SNPs \[−2578C\>A (rs699947), −634C\>G (rs2010963), and +936C\>T (rs3025039)\] in the *VEGF* gene. Values in squares are LD between single markers.](medscimonit-21-3474-g001){#f1-medscimonit-21-3474}

![Electrophoresis patterns for the genotypes of *VEGF* rs699947 (−2578C\>A) polymorphism analyzed by PCR-RFLP-based assay. Lane M shows DNA marker. Lanes 3, 5, and 7 (324bp) show individuals with CC genotype. Lanes 4 and 9 (202bp and 122bp) show those with AA genotype. Lanes 1, 6, and 8 (324bp, 202bp and 122bp) show those with CA genotype.](medscimonit-21-3474-g002){#f2-medscimonit-21-3474}

![Electrophoresis patterns for the genotypes of *VEGF* rs2010963 (−634C\>G) polymorphism analyzed by PCR-RFLP-based assay. Lane M shows DNA marker. Lanes 4, 6 and 7 (180bp) show individuals with CC genotype. Lanes 1, 3, 5 and 9 (180bp, 120bp, and 60bp) show those with CG genotype. Lanes 2 and 8 (60bp and 120bp) show those with GG genotype.](medscimonit-21-3474-g003){#f3-medscimonit-21-3474}

![Electrophoresis patterns for the genotypes of *VEGF* rs3025039 (+936C\>T) polymorphism analyzed by PCR-RFLP-based assay. Lane M shows DNA marker. Lanes 1, 6, and 8 (198bp) show individuals with CC genotype. Lanes 2, 5, and 9 (86bp and 112bp) show those with TT genotype. Lanes 3, 4, 7, and 10 (198bp, 86bp, and 112bp) show those with CT genotype.](medscimonit-21-3474-g004){#f4-medscimonit-21-3474}

###### 

Primers used for amplification of the *VEGF* genetic polymorphisms.

  SNP                             Alias name   Annealing Temperature (°C)   Primers for PCR amplification   Restriction enzyme
  ------------------------------- ------------ ---------------------------- ------------------------------- --------------------
  rs699947                        −2578C\>A    53                           F: 5′-CATACCGATGGAACTGG-3′      Bg1II
  R: 5′-GTTTCTGACCTGGCTATTT-3′                                                                              
  rs2010963                       −634C\>G     67                           F: 5′-CGACGGCTTGGGGAGATTGC-3′   BsmFI
  R: 5′-GGGCGGTGTCTGTCTGTCTG-3′                                                                             
  rs3025039                       936C\>T      53                           F: 5′-AGGGTTTCGGGAACCACATC-3′   NlaIII
  F: 5′-AGGGTTTCGGGAACCACATC-3′                                                                             

SNP -- single nucleotide polymorphism; PCR -- polymerase chain reaction; F -- forward; R -- reward.

###### 

The comparison of baseline characteristics between Chinese Han children with tetralogy of Fallot (TOF patients) and normal Chinese Han children (healthy controls).

  Clinical characteristics   TOF patients (n=160)   Healthy controls (n=240)   *P* value
  -------------------------- ---------------------- -------------------------- -------------------------------------------------------------
  Age                        4.27±1.93              5.68±2.17                  \<0.0001[a](#tfn3-medscimonit-21-3474){ref-type="table-fn"}
  BMI                        16.03±3.36             16.28±2.63                 0.406[a](#tfn3-medscimonit-21-3474){ref-type="table-fn"}
  Gender (male/female)       103/57                 148/92                     0.583[b](#tfn4-medscimonit-21-3474){ref-type="table-fn"}
  Family history of TOF      38/122(23.8%)          23/217(9.6%)               0.0001[b](#tfn4-medscimonit-21-3474){ref-type="table-fn"}

TOF -- tetralogy of Fallot; BMI -- body mass index;

*p* value of student's t test;

chi-square test.

###### 

The comparisons of genotypes and allele frequency distribution of *VEGF* genetic polymorphisms (−2578C\>A, −634C\>G and 936C\>T) between case group (TOF group) and control group (healthy controls).

  Genotype    TOF patients (n=160)   Healthy controls (n=240)   OR (95%CI)          χ^2^    *P* value
  ----------- ---------------------- -------------------------- ------------------- ------- -----------
  −2578C\>A                                                                                 
   CC         10 (6.2%)              23 (9.6%)                  Reference                   
   CA         72 (45%)               138 (57.5%)                1.20 (0.54--2.66)   0.202   0.653
   AA         78 (48.8%)             79 (32.9%)                 2.27 (1.01--5.08)   4.118   0.042
   AA+CA      150 (93.8%)            217 (90.4%)                1.59 (0.74--3.44)   1.409   0.235
   C allele   92 (28.8%)             184 (38.3%)                Reference                   
   A allele   228 (71.2%)            296 (61.7%)                1.54 (1.14--2.09)   7.803   0.005
  −634C\>G                                                                                  
   CC         13 (8.1%)              29 (12.0%)                 Reference                   
   CG         61 (38.1%)             123 (51.3%)                1.11 (0.54--2.28)   0.075   0.784
   GG         86 (53.8%)             88 (36.7%)                 2.18 (1.06--4.47)   4.651   0.031
   GG+CG      147 (91.9%)            211 (81.9%)                1.55 (0.78--3.09)   1.601   0.206
   C allele   87 (27.2%)             181 (37.7%)                Reference                   
   G allele   233 (72.8%)            299 (62.3%)                1.62 (1.19--2.21)   9.540   0.002
  936C\>T                                                                                   
   CC         73 (45.6%)             89 (37.1%)                 Reference                   
   CT         20 (12.5%)             20 (8.3%)                  1.22 (0.61--2.44)   0.315   0.575
   TT         67 (41.9%)             131 (54.6%)                0.62 (0.41--0.96)   4.723   0.030
   TT+CT      87 (54.4%)             151 (62.9%)                1.42 (0.96--2.14)   2.907   0.088
   C allele   166 (51.9%)            198 (41.3%)                Reference                   
   T allele   154 (48.1%)            282 (58.7%)                0.65 (0.49--0.87)   8.741   0.003

TOF -- tetralogy of Fallot; OR -- odds ratio; 95%CI -- 95% confidence interval.

###### 

The results of linkage analysis of SNP in VEGF gene.

  Linked genes          D′      r^2^
  --------------------- ------- -------
  rs699947-rs2010963    0.138   0.627
  rs699947-rs3025039    0.256   0.694
  rs2010963-rs3025039   0.009   0.198

###### 

The multivariate logistic regression analysis of *VEGF* gene polymorphisms in the risk of tetralogy of Fallot.

  Variables   S.E     Wald    Sig       Exp(B)   95%CI
  ----------- ------- ------- --------- -------- --------------
  −2578C\>A   0.215   9.662   0.002     1.951    1.280--2.974
  −634C\>G    0.213   6.181   \<0.001   2.144    1.411--3.258
  936C\>T     0.213   0.339   0.013     0.590    0.389--0.894

S.E -- standard error of regression; Wald -- Wald χ^2^; Sig -- significance, *P* value; Exp(B) -- adjusted odds ratio, OR value; 95%CI -- 95% confidence interval.
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